AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8915237 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME) (Hygrobac‐DAR)
Number of subjects: 15
Study 1860433 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal suction 6-hourly
Number of subjects: 0
Study 1860433 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal suction 12-hourly
Number of subjects: 0
Study 6434794 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide 10 mg/d for 6 weeks
Number of subjects: 40
Study 30249082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiperspirant product containing agaricine, aluminum hydrochloride, and silver citrate, applied once in a laboratory setting and then used at home for 14 days.
Number of subjects: 20
Study 30249082 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiperspirant product after repeated home applications for 14 days.
Number of subjects: 20
Study 29907752 — intervention group
Group type: EXPERIMENTAL
Intervention: microcrystalline cellulose pellets (500 mg samples)
Number of subjects: 132
Study 28028984 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation (WBC) with subsequent kinesiotherapy
Number of subjects: 32
Study 28028984 — intervention group
Group type: COMPARATOR
Intervention: Kinesiotherapy (KT)
Number of subjects: 32
Study 25493120 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb
Number of subjects: 219
Study 21655909 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-etched titanium caps
Number of subjects: 10
Study 21655909 — intervention group
Group type: COMPARATOR
Intervention: Machined titanium caps
Number of subjects: 10
Study 20093909 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily gentamicin (5 mg/kg IV, then 2 placebo doses IV after 8 and 16 hours)
Number of subjects: 126
Study 20093909 — intervention group
Group type: COMPARATOR
Intervention: 8-hour gentamicin (2 mg/kg IV, then 1.5 mg/kg IV after 8 and 16 hours)
Number of subjects: 126
Study 20093909 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received ampicillin (2 grams IV every 6 hours for a total of four doses) and patients who underwent cesarean delivery also received clindamycin (900 mg IV every 8 hours, for a total of three doses).
Number of subjects: 126
Study 17268894 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 20
Study 17268894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16351337 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare and antipoverty policies during the transition into middle childhood
Number of subjects: 30000
Study 16351337 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare and antipoverty policies during the transition out of middle childhood into early adolescence
Number of subjects: 30000
Study 11862965 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP monitoring group
Number of subjects: 164
Study 11862965 — intervention group
Group type: COMPARATOR
Intervention: PEF monitoring group
Number of subjects: 164
Study 11862965 — intervention group
Group type: EXPERIMENTAL
Intervention: ECP and PEF monitoring groups
Number of subjects: 164
Study 10207779 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC 20 regimen (Omeprazole 20 mg daily, Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Number of subjects: 224
Study 10207779 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC 30 regimen (Lansoprazole 30 mg daily, Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Number of subjects: 224
Study 10207779 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC 40 regimen (Omeprazole 20 b.d., Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Number of subjects: 224
Study 7617349 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 80
Study 7617349 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 80
Study 7617349 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia
Number of subjects: 80
Study 7617349 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 80
Study 2171275 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzonal
Number of subjects: 40
Study 2171275 — intervention group
Group type: EXPERIMENTAL
Intervention: Finlepsin
Number of subjects: 40
Study 334315 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage haloperidol (100 mg daily) for three months
Number of subjects: 0
Study 334315 — intervention group
Group type: COMPARATOR
Intervention: Control group (chlorpromazine)
Number of subjects: 0
Study 334315 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage haloperidol (100 mg daily)
Number of subjects: 0
Study 334315 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up period after haloperidol
Number of subjects: 0
Study 30754068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 64
Study 30754068 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 64
Study 31385001 — intervention group
Group type: COMPARATOR
Intervention: Quizartinib 30 mg alone (reference)
Number of subjects: 64
Study 31385001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg once daily (days 1-5) + single-dose quizartinib 30 mg (day 5) (test)
Number of subjects: 64
Study 31385001 — intervention group
Group type: COMPARATOR
Intervention: Quizartinib alone
Number of subjects: 64
Study 31385001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole + quizartinib
Number of subjects: 64
Study 26873392 — intervention group
Group type: EXPERIMENTAL
Intervention: Anise oil
Number of subjects: 120
Study 26873392 — intervention group
Group type: COMPARATOR
Intervention: Colpermin
Number of subjects: 120
Study 26873392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26337978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg/vilanterol 25 μg once-daily
Number of subjects: 0
Study 26337978 — intervention group
Group type: COMPARATOR
Intervention: Existing therapy (control group)
Number of subjects: 0
Study 23578227 — intervention group
Group type: EXPERIMENTAL
Intervention: N7‐GP 25 μg kg(‐1)
Number of subjects: 23
Study 23578227 — intervention group
Group type: EXPERIMENTAL
Intervention: N7‐GP 100 μg kg(‐1)
Number of subjects: 23
Study 23578227 — intervention group
Group type: EXPERIMENTAL
Intervention: N7‐GP 200 μg kg(‐1)
Number of subjects: 23
Study 23578227 — intervention group
Group type: EXPERIMENTAL
Intervention: N7‐GP (all doses)
Number of subjects: 23
Study 23578227 — intervention group
Group type: COMPARATOR
Intervention: Observation period with on-demand treatment of rFVIIa
Number of subjects: 23
Study 21119069 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 0
Study 19188550 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (62.5 mg on day 1, 125 mg on days 2 and 3)
Number of subjects: 11
Study 19188550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17307892 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (1500 impulses at 14 KV)
Number of subjects: 50
Study 17307892 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (nonsteroidal anti-inflammatory drugs, physiotherapy, exercise program, knee strap)
Number of subjects: 50
Study 17307892 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Number of subjects: 50
Study 17307892 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 50
Study 14996107 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% melatonin applied once daily for 6 months
Number of subjects: 40
Study 14996107 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution applied once daily for 6 months
Number of subjects: 40
Study 11697758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (0.5 mg bid)
Number of subjects: 12
Study 11697758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (0.5 mg bid) + Verapamil (80 mg tid)
Number of subjects: 12
Study 9458447 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (low dose)
Number of subjects: 1209
Study 9458447 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (medium dose)
Number of subjects: 1209
Study 9458447 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogatran (high dose)
Number of subjects: 1209
Study 9458447 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1209
Study 9458447 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1209
Study 8198309 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 98
Study 8198309 — intervention group
Group type: COMPARATOR
Intervention: 0.5% diphenhydramine
Number of subjects: 98
Study 3370405 — intervention group
Group type: EXPERIMENTAL
Intervention: Salad with toppings (600 g) with small beverage
Number of subjects: 10
Study 3370405 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated beverage (800 ml)
Number of subjects: 10
Study 3370405 — intervention group
Group type: EXPERIMENTAL
Intervention: Bean burritos and one bean tostada (900 g) with small beverage
Number of subjects: 10
Study 29666118 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial R-chemotherapy ± R maintenance
Number of subjects: 1135
Study 29666118 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMA-prognostic index (PRIMA-PI)
Number of subjects: 1135
Study 29666118 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort (FL2000 LYSA trial and University of Iowa/Mayo Clinic)
Number of subjects: 1135
Study 28689041 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 65
Study 28689041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 65
Study 26254752 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride (ultrashort‐acting β‐blocker)
Number of subjects: 60
Study 26254752 — intervention group
Group type: COMPARATOR
Intervention: Control group (no landiolol)
Number of subjects: 60
Study 26254752 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol hydrochloride
Number of subjects: 60
Study 23823157 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin with twice-daily radiation
Number of subjects: 93
Study 23823157 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus cisplatin with twice-daily radiation
Number of subjects: 93
Study 20701479 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 45
Study 20701479 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 45
Study 20701479 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 45
Study 18552270 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin stimulating agents (ESAs)
Number of subjects: 0
Study 16616165 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patch (NP)
Number of subjects: 130
Study 16616165 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 mg nicotine patch (NP)
Number of subjects: 130
Study 15030300 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies targeted against reactive oxygen intermediates (not specified dosage or duration)
Number of subjects: 0
Study 15030300 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (not specified dosage or duration)
Number of subjects: 0
Study 10985710 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ST-segment elevation MI patients
Number of subjects: 881
Study 10985710 — intervention group
Group type: COMPARATOR
Intervention: ST-segment elevation MI patients
Number of subjects: 881
Study 8618139 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2000 or 3000 mg for 16 weeks)
Number of subjects: 22
Study 1466444 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25%
Number of subjects: 30
Study 1466444 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5%
Number of subjects: 30
Study 1466444 — intervention group
Group type: COMPARATOR
Intervention: Control (no bupivacaine)
Number of subjects: 30
Study 6741150 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 times 250 ml protein‐free dialysate of calf blood (Solcoseryl) in saline solution over 9 days
Number of subjects: 0
Study 6741150 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28570494 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-guided training (HRVG)
Number of subjects: 36
Study 28570494 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study 29641184 — intervention group
Group type: COMPARATOR
Intervention: Messaging-only arm (n = 237)
Number of subjects: 589
Study 29641184 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard testing arm (n = 173)
Number of subjects: 589
Study 29641184 — intervention group
Group type: EXPERIMENTAL
Intervention: Test kit arm (n = 179)
Number of subjects: 589
Study 26560732 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance CT colonography (CTC)
Number of subjects: 82
Study 26560732 — intervention group
Group type: COMPARATOR
Intervention: Preliminary colonoscopy (OC)
Number of subjects: 82
Study 26560732 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance CTC
Number of subjects: 82
Study 24120672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (15μg HA/strain)
Number of subjects: 636
Study 24120672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (21μg HA/strain)
Number of subjects: 636
Study 24120672 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intramuscular vaccine (60μg HA/strain)
Number of subjects: 636
Study 24120672 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose intramuscular vaccine (15μg HA/strain)
Number of subjects: 636
Study 22674470 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution of 10 μg deuterated Phenanthrene ([D₁₀]Phe)
Number of subjects: 25
Study 22674470 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cigarettes containing 10 μg deuterated Phenanthrene ([D₁₀]Phe)
Number of subjects: 25
Study 22674470 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1-null subjects
Number of subjects: 25
Study 19288563 — intervention group
Group type: EXPERIMENTAL
Intervention: CME with practice enablers and reinforcers (PER)
Number of subjects: 122
Study 19288563 — intervention group
Group type: COMPARATOR
Intervention: CME only (control group)
Number of subjects: 122
Study 17635247 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP/BG
Number of subjects: 29
Study 17635247 — intervention group
Group type: COMPARATOR
Intervention: BG
Number of subjects: 29
Study 16175592 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise bronchial challenge test
Number of subjects: 545
Study 12232564 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.15 mg/kg at a rate of 2 mg/min)
Number of subjects: 223
Study 12232564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg over 10 minutes)
Number of subjects: 223
Study 12232564 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and/or ibutilide
Number of subjects: 223
Study 12232564 — intervention group
Group type: COMPARATOR
Intervention: Verapamil and ibutilide
Number of subjects: 223
Study 10086657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg twice daily) plus metronidazole (400 mg) and tetracycline (500 mg) four times daily for 1 week (RMT)
Number of subjects: 100
Study 10086657 — intervention group
Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (120 mg), metronidazole (400 mg), and tetracycline (500 mg) four times daily for 1 week (BMT)
Number of subjects: 100
Study 10086657 — intervention group
Group type: EXPERIMENTAL
Intervention: RMT
Number of subjects: 100
Study 10086657 — intervention group
Group type: COMPARATOR
Intervention: BMT
Number of subjects: 100
Study 7722691 — intervention group
Group type: EXPERIMENTAL
Intervention: CT1 (1 period of intervention, n = 113)
Number of subjects: 301
Study 7722691 — intervention group
Group type: EXPERIMENTAL
Intervention: CT2 (2 periods of intervention, n = 64)
Number of subjects: 301
Study 7722691 — intervention group
Group type: EXPERIMENTAL
Intervention: CT3 (3 periods of intervention, n = 62)
Number of subjects: 301
Study 7722691 — intervention group
Group type: EXPERIMENTAL
Intervention: CT4 (4 periods of intervention, n = 62)
Number of subjects: 301
Study 2397315 — intervention group
Group type: EXPERIMENTAL
Intervention: Case vignette with diagnosis of alcohol dependence
Number of subjects: 0
Study 2397315 — intervention group
Group type: COMPARATOR
Intervention: Case vignette without diagnosis of alcohol dependence
Number of subjects: 0
Study 7394499 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg oxitropium bromide
Number of subjects: 15
Study 7394499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7394499 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg oxitropium bromide at 7.30 a.m. after placebo
Number of subjects: 15
Study 31090589 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target (T2T) strategy
Number of subjects: 0
Study 31090589 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 27615515 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-game exercise (n=30)
Number of subjects: 60
Study 27615515 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (n=30)
Number of subjects: 60
Study 25860402 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 73
Study 25860402 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 73
Study 25860402 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 73
Study 25860402 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 73
Study 20646754 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for parents
Number of subjects: 0
Study 20646754 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 19438539 — intervention group
Group type: EXPERIMENTAL
Intervention: M. vaccae (intradermal injection, three times at 2-week intervals)
Number of subjects: 129
Study 19438539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intradermal injection, three times at 2-week intervals)
Number of subjects: 129
Study 17416453 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar TURP
Number of subjects: 100
Study 17416453 — intervention group
Group type: COMPARATOR
Intervention: TURIS (Bipolar TURP)
Number of subjects: 100
Study 17416453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 15145972 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (OM) 20 mg bid with bismuth biskalcitrate, metronidazole, and tetracycline
Number of subjects: 34
Study 15145972 — intervention group
Group type: COMPARATOR
Intervention: Bismuth biskalcitrate, metronidazole, and tetracycline alone
Number of subjects: 34
Study 11240988 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg
Number of subjects: 90
Study 11240988 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 20 microg/kg
Number of subjects: 90
Study 11240988 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 0.2 mg/kg
Number of subjects: 90
Study 9699568 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion
Number of subjects: 20
Study 9699568 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 8076440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 1 alpha‐OHD3 (80 ng/kg BW)
Number of subjects: 8
Study 8076440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of 1 alpha‐OHD3 (80 ng/kg BW)
Number of subjects: 8
Study 8076440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 1 alpha‐OHD3 (80 ng/kg BW)
Number of subjects: 8
Study 2760214 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 72
Study 2760214 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 72
Study 2760214 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy for 3 months
Number of subjects: 72
Study 2760214 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic estrogen therapy
Number of subjects: 72
Study 20683 — intervention group
Group type: EXPERIMENTAL
Intervention: methantheline bromide
Number of subjects: 34
Study 20683 — intervention group
Group type: EXPERIMENTAL
Intervention: flavoxate chloride
Number of subjects: 34
Study 20683 — intervention group
Group type: EXPERIMENTAL
Intervention: meladrazine tartrate
Number of subjects: 34
Study 20683 — intervention group
Group type: COMPARATOR
Intervention: cystometric studies
Number of subjects: 34
Study 30566177 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX) 380 mg every 4 weeks
Number of subjects: 159
Study 30566177 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BP-NLX) flexible doses (4-24 mg; target dosage 16 mg/d)
Number of subjects: 159
Study 30566177 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX
Number of subjects: 159
Study 27679664 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMPle intervention (arm A)
Number of subjects: 2560
Study 27679664 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMPle intervention (arm B)
Number of subjects: 2560
Study 27679664 — intervention group
Group type: COMPARATOR
Intervention: Usual practice control
Number of subjects: 2560
Study 27137147 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA in fed condition
Number of subjects: 36
Study 27137147 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA in fasted condition
Number of subjects: 36
Study 27137147 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA in fasted state for elderly subjects
Number of subjects: 36
Study 23625291 — intervention group
Group type: EXPERIMENTAL
Intervention: Plecanatide (0.1 to 48.6 mg)
Number of subjects: 72
Study 23625291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 20971975 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (8 mg once daily for 8 weeks)
Number of subjects: 15
Study 20971975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15